BioCryst Pharmaceuticals Cash Flow Statement
NASDAQ: BCRXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
BioCryst Pharmaceuticals free cash flow
In fiscal 2025, BioCryst Pharmaceuticals generated $347.4 million of operating cash flow and spent $2.5 million on capital expenditures. That left free cash flow of $344.9 million, a free-cash-flow margin of 39.4% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
BioCryst Pharmaceuticals cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 263.86M | -88.88M | -226.54M | -247.12M | -184.06M | -182.81M | -108.90M | -101.25M | -65.78M | -55.14M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 1.39M | 1.25M | 1.66M | 1.44M | 777.00K | 748.00K | 724.00K | 770.00K | 704.00K | 483.00K |
| Stock-Based Compensation | 85.07M | 65.41M | 55.62M | 44.70M | 34.64M | 14.79M | 17.72M | 9.40M | 12.62M | 8.49M |
| Change in Working Capital | 11.53M | -10.13M | -3.06M | -58.95M | 3.96M | 20.11M | -3.93M | -3.28M | 6.22M | -9.87M |
| Operating Cash Flow | 347.37M | -52.02M | -95.14M | -161.85M | -142.16M | -135.11M | -89.58M | -92.56M | -41.14M | -53.44M |
| Capital Expenditures | -2.47M | -1.12M | -2.17M | -1.35M | -2.38M | -514.00K | -343.00K | -366.00K | -328.00K | -5.28M |
| Investing Cash Flow | -13.69M | 52.59M | -131.50M | -128.24M | 15.80M | -6.86M | 77.93M | 4.77M | -64.64M | 23.27M |
| Debt Issued | 0 | 0 | 300.00M | 73.07M | 0 | — | — | — | — | — |
| Debt Repaid | -300.00M | 0 | -240.45M | — | — | — | — | — | — | — |
| Financing Cash Flow | -349.93M | -5.76M | 32.48M | 88.03M | 359.67M | 300.59M | 99.10M | 62.50M | 135.70M | 23.30M |
| Net Change in Cash | -14.99M | -6.12M | -193.79M | -201.50M | 233.39M | 158.63M | 87.45M | -25.29M | 29.92M | -6.86M |
| Free Cash Flow | 344.90M | -53.14M | -97.31M | -163.20M | -144.54M | -135.62M | -89.93M | -92.93M | -41.47M | -58.72M |
This table shows 10 annual periods of BioCryst Pharmaceuticals's cash flow statement, from FY 2025 back to FY 2016, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow BCRX's reporting calendar. What is a cash flow statement?